BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — Brainstorm Cell receives Nasdaq delisting notice; files appeal to stay trading

BRAINSTORM CELL THERAPEUTICS INC.

Received Staff Letter on May 1, 2024 for failing to meet $1.00 minimum bid price by April 29, 2024.
Submitted hearing request to Nasdaq Hearings Panel on May 2, 2024 to appeal delisting determination.
Suspension and Form 25-NSE stayed pending final Panel decision; trading continues under BCLI.
No assurance that Panel will grant an exception or that compliance will be regained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 1, 2024, the Company received a staff determination letter (“Staff Letter”) from the Staff of Nasdaq indicating that the Company had not regained compliance with the Minimum Bid Price Requirement by April 29, 2024. Pursuant to the Nasdaq Listing Rules and the Staff Letter, if the Company does not request an appeal of the Staff’s determination by May 8, 2024, the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on May 10, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-056971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.